Abstract
Prostaglandins and analogues for therapeutic use gained importance in the early eighties, when a substantial number of clinical studies about their therapeutical effects was published6, 12, 17, 22. Out of the huge family of prostanoids, prostaglandins E1 (PG E1) and I2 and their synthetical analogues are the most important substances in clinical practice in the field of solid organ transplantation. Organ procurement and organ preservation4, 5, 9, 15, 19 as well as treatment of primary graft failure8, 10 have been described as possible indications for PG E1. Vasodilating effects of prostaglandins are mediated by increasing cAMP levels in vascular smooth muscle cells. This mediation by cAMP is shared with beta-agonists and phosphodiesterase-inhibitors, but not with nitrates and nitric oxide3, 14, 21. Treatment of elevated pulmonary vascular resistance (PVR), which is frequently needed after heart transplantation (HTX), and in the pretransplant evaluation as well as bridging to transplan-tation1, 7, 20 has been the indication for PG E1 in our patient cohort.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Armitage G., Hardesty R. et al., Prostaglandin E1: An effective treatment of right heart failure after cardiac transplantation. J Heart Transplant 6:348–51 (1987)
Cawello W., Leonhardt A., Schweer H. et al, Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Br J Pharmacol. 40(3): 273–6 (1995)
Fullerton D., Hahn A. et al, Pulmonary vascular smooth muscle cell relaxation by cGMP-versus cAMP-mediated mechanisms. J Surg Res. 57(2): 259–63 (1994)
Harjula A., Baldwin J. et al, Clinical heart lung preservation with Prostaglandin E1. Transpl Proc. 19: 4101 (1987)
Hide EJ., Ney P., Piper J. et al., Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels. BrJ Pharmacol. 116(5): 2435–40 (1995)
Higenbottam T, Wheeldon D et al., Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (Prostacyclin). Lancet 12: 1046–7 (1984)
Iberer F., Wasler A. et al., Prostaglandin E1 induced moderation of elevated pulmonary vascular resistance. Survival on waiting list and results of orthotopic heart transplantation. J Heart Lung Transplant 12(2): 173–8 (1993)
Iberer F., Müller H. et al., Prostaglandin E1 in der Therapie der Abstoßung und des pulmonalen Hypertonus im Rahmen der Herztransplantation. Immundiagnostik und Immuntherapie in der modernen Intensivmedizin, Vogt S., ed., Pabst-Verlag, Lengerich (1993)
Kim Y., Kai T. et al., Hepatoprotection by a PG I2 analogue in complete wann ischemia of the pig liver. Prostanoid release from the reperfused liver. Transplantation 58(8): 875–9 (1994)
Moran M., Mozes M. et al., Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med. 322: 1183–88 (1990)
Murali S., Uretsky B., Armitage J. et al., Utility of Prostaglandin E1 in the Pretransplantation Evaluation of Heart Failure Patients with Significant Pulmonary Hypertension. J Heart Lung Transplant. 11: 716–23(1991)
Naeije R., Melot C et al., Reduction in pulmonary hypertension by prostaglandin E1 in decompensated chronic obstructive pulmonary disease. Am Rev Despir Dis. 125: 1–5 (1982)
Pacher R., Globits S., Wutte M. et al., Beneficial hemodynamic effects of prostaglandin E1 infusion in catecholamine-dependent heart failure: results of a prospective, randomized controlled study. Crit Care Med. 22(7): 1084–90 (1994)
Prielipp R., McLean R. et al., Hemodynamic profiles of prostaglandin E1, isoproterenol, prostacyclin and nifedipin in experimental porcine pulmonary hypertension. Crit Care Med. 19(1): 60–7 (1991)
Quiroga J., Prieto J., Liver cytoprotection by prostaglandins. Pharmacol Ther. 58(1): 67–91 (1993)
Schweer H., Cawello W., Seyberth HW, Gas chromatogryphy negative ion chemical ionization triple quadrupole mass spectometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2, 3, 4, 5, 20-pentanor-19-carboprostanoic acid in plasma. Prostaglandins Leukot Essent Fatty Acids. 51(6): 401–5(1994)
Sinzinger H., Rogatti W., Prostaglandin E1 in der Therapie der peripheren arteriellen Durchblutungsstörung. Wiener Klinische Wochenschrift 103/18: 558–565 (1991)
Sorbara C, Pitarello D. et al., Prostaglandine in der Intensivmedizin und bei Herztransplantationen. Translation from A.P.I. C.E; Vol. 8: 327–337 (1993)
Ueno T., Horita K. et al., The effect of Prostaglandin E1 on heart preservation. Transplantation 54(3): 418–22 (1992)
Vincent J., Carlier E. et al., Prostaglandin E1 infusion for right ventricular failure after after cardiac transplantation. J Thorac Cardiovasc Surgery. 103: 33–39 (1992)
Warren J., Wilson A. et al., Opposing roles of cyclic AMP in the vascular control of edema formation. FASEB J. 7(14): 1394–400 (1993)
Watkins W., Peterson M. et al., Prostacyclin and Prostaglandin E1 for severe idiopathic pulmonary hypertension. Lancet I. 1083 (1981)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media New York
About this chapter
Cite this chapter
Müller, H. et al. (1997). Practical Aspects of Prostaglandin E1 before and after Solid Organ Transplantation. In: Sinzinger, H., Samuelsson, B., Vane, J.R., Paoletti, R., Ramwell, P., Wong, P.YK. (eds) Recent Advances in Prostaglandin, Thromboxane, and Leukotriene Research. Advances in Experimental Medicine and Biology, vol 433. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1810-9_2
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1810-9_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1812-3
Online ISBN: 978-1-4899-1810-9
eBook Packages: Springer Book Archive